ArticleBMC gastroenterology2026
The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines recommend pancolonic chromoendoscopy (pCE) over white light endoscopy (WLE) alone for colorectal neoplasia (CRN) detection in individuals with inflammatory bowel diseases (IBD). However, these techniques are poorly adopted due to technical and logistical limitations. Artificial intelligence-based computer-aided detection (CADe) is a promising new technology integrated into modern endoscopy platforms that has been shown to increase CRN detection in the non-IBD population. We aim to compare CADe-guided colonoscopy to chromoendoscopy in a randomized controlled trial (RCT) in individuals with IBD undergoing surveillance colonoscopy.
methodsThis is a pragmatic, multicenter, parallel-group, open-label, non-inferiority RCT comparing CADe-guided colonoscopy (intervention) to pCE (virtual or dye spray) (standard of care). Consenting adults (≥ 18 years) with longstanding (≥ 8 years) IBD (or any duration with primary sclerosing cholangitis) involving ≥ 1/3 of the colorectum, in clinical remission and undergoing surveillance colonoscopy, will be included. Those who undergo a high-quality colonoscopy (adequate preparation, minimal inflammation, complete intubation) will be included in the primary analysis. Patients will be centrally randomized by permuted blocks, stratified by endoscopist. The anticipated CRN rate is 15% in both groups. To demonstrate non-inferiority with a 7.5% margin, at a one-sided alpha of 2.5% and 80% power, and allowing for a 5% loss of eligibility, a total of 752 participants are required. The primary outcome will be visible CRN detected at colonoscopy; secondary outcomes include the mean number of CRN, proportion of individuals with high-risk CRN, procedural time, adverse events, and endoscopist acceptance, with per-protocol (primary) and intention-to-treat (secondary) analyses. This protocol follows the SPIRIT 2025 guidelines. DISCUSSION: AI has shown potential in enhancing CRN detection, but current AI systems are not specifically trained for IBD-related lesions, limiting effectiveness. This multicenter non-inferiority RCT will, for the first time, directly compare CADe-guided colonoscopy to pCE for CRN detection in individuals with IBD. This approach may increase adoption of AI-enhanced endoscopy and improve cancer prevention strategies.
trial registrationAustralian New Zealand Clinical Trials Registry (ANZCTR) registration number: ACTRN12626000102370. At the time of initial submission (November 2025), recruitment for this study had not started. Participant enrollment began in April 2026, and as of June 8, 2026, 19 out of the target 752 participants have been recruited. The study is currently in the active recruitment phase and has not yet transitioned to follow-up only.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.